Component

Compound C / dorsomorphin

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Compound C blocked fisetin-induced apoptosis in human U266 cells.

    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Pharmacological AMPK-pathway perturbation.
    limitations
    Compound C has off-target activity; this is not equivalent to AMPK-specific genetic proof.
    nutrient_topic
    Fisetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Fisetin
    plain_language
    A kinase-pathway inhibitor also weakened the response.
    primary_references
    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22261340/ · DOI 10.1016/j.canlet.2012.01.008
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Fisetin: metabolism, cell-state responses and cross-nutrient mechanisms (2026-09-19) · lines 384–390

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Pharmacological AMPK-pathway perturbation. · source_derived_draft · unverified_draft

    ## fisetin-u266-ampk-inhibitor A kinase-pathway inhibitor also weakened the response. Compound C blocked fisetin-induced apoptosis in human U266 cells. Model: Pharmacological AMPK-pathway perturbation. Limitations: Compound C has off-target activity; this is not equivalent to AMPK-specific genetic proof. Evidence access: Primary abstract Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22261340/ · DOI 10.1016/j.canlet.2012.01.008
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards